Neurologic autoimmunity and immune checkpoint inhibitors

Objective To describe neural autoantibody profiles and outcomes in patients with neurologic autoimmunity associated with immune checkpoint inhibitor (ICI) cancer immunotherapy. Methods In this retrospective descriptive study, 63 patients with ICI-related neurologic autoimmunity were included: 39 seen at the Mayo Clinic Neurology Department (clinical cohort) and 24 whose serum/CSF was referred to the Mayo Clinic Neuroimmunology Laboratory for autoantibody testing. Serum/CSF samples were tested for neural-specific autoantibodies. Predictors of unfavorable outcome (residual adverse event severity grade ≥3) were explored (logistic regression). Results Median age at neurologic symptom onset was 65 years (range 31–86); 40% were female. Neurologic manifestations were CNS-restricted (n = 26), neuromuscular (n = 30), combined (n = 5), or isolated retinopathy (n = 2). Neural-specific autoantibodies were common in patients with CNS involvement (7/13 [54%] in the unbiased clinical cohort) and included known or unidentified neural-restricted specificities. Only 11/31 patients with CNS manifestations had neuroendocrine malignancies typically associated with paraneoplastic autoimmunity. Small-cell lung cancer (SCLC)–predictive antibodies were seen in 3 patients with non-neuroendocrine tumors (neuronal intermediate filament immunoglobulin G [IgG] and antineuronal nuclear antibody 1 with melanoma; amphiphysin IgG with non-SCLC). A median of 10 months from onset (range, 0.5–46), 14/39 in the clinical cohort (36%) had unfavorable outcomes; their characteristics were age ≥70 years, female, CNS involvement, lung cancer, higher initial severity grade, and lack of systemic autoimmunity. By multivariate analysis, only age remained independently associated with poor outcome (p = 0.01). Four of 5 patients with preexistent neurologic autoimmunity experienced irreversible worsening after ICI. Conclusions Neural-specific autoantibodies are not uncommon in patients with ICI-related CNS neurologic autoimmunity. Outcomes mostly depend on the pre-ICI treatment characteristics and clinical phenotype.

[1]  S. Pittock,et al.  CRMP5-IgG-Associated Paraneoplastic Myelopathy With PD-L1 Inhibitor Therapy. , 2019, JAMA neurology.

[2]  A. Pruitt,et al.  A case series of PD-1 inhibitor-associated paraneoplastic neurologic syndromes , 2019, Journal of Neuroimmunology.

[3]  R. Sullivan,et al.  Varied phenotypes and management of immune checkpoint inhibitor-associated neuropathies , 2019, Neurology.

[4]  V. Lennon,et al.  Neurologic Autoimmunity in the Era of Checkpoint Inhibitor Cancer Immunotherapy. , 2019, Mayo Clinic proceedings.

[5]  H. Lassmann,et al.  PDE10A antibodies in autoimmune encephalitis , 2019, Neurology.

[6]  C. Lucchinetti,et al.  Phosphodiesterase 10A IgG , 2019, Neurology.

[7]  F. Ducray,et al.  Increased frequency of anti-Ma2 encephalitis associated with immune checkpoint inhibitors , 2019, Neurology: Neuroimmunology & Neuroinflammation.

[8]  D. Scheie,et al.  Neuromuscular adverse events associated with anti-PD-1 monoclonal antibodies , 2018, Neurology.

[9]  V. Lennon,et al.  Paraneoplastic autoimmunity and small‐cell lung cancer: Neurological and serological accompaniments , 2019, Thoracic cancer.

[10]  A. Mammen,et al.  Pre-existing antiacetylcholine receptor autoantibodies and B cell lymphopaenia are associated with the development of myositis in patients with thymoma treated with avelumab, an immune checkpoint inhibitor targeting programmed death-ligand 1 , 2018, Annals of the rheumatic diseases.

[11]  C. Lucchinetti,et al.  Paraneoplastic neuronal intermediate filament autoimmunity , 2018, Neurology.

[12]  S. Minami,et al.  Lambert-Eaton Myasthenic Syndrome Caused by Nivolumab in a Patient with Squamous Cell Lung Cancer , 2018, Case Reports in Neurology.

[13]  N. Weiss,et al.  Immune checkpoint inhibitor-related myositis and myocarditis in patients with cancer , 2018, Neurology.

[14]  U. Topaloglu,et al.  Severe neurologic complications of immune checkpoint inhibitors: a single-center review , 2018, Journal of Neurology.

[15]  S. Irani,et al.  Seronegative antibody‐mediated neurology after immune checkpoint inhibitors , 2018, Annals of clinical and translational neurology.

[16]  M. Suarez‐Almazor,et al.  Management of Immune-Related Adverse Events in Patients Treated With Immune Checkpoint Inhibitor Therapy: American Society of Clinical Oncology Clinical Practice Guideline. , 2018, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[17]  J. Sawada,et al.  Neuromyelitis optica spectrum disorder secondary to treatment with anti-PD-1 antibody nivolumab: the first report , 2018, BMC Cancer.

[18]  M. Lotem,et al.  Neurologic complications of immune checkpoint inhibitors , 2018, Journal of Neuro-Oncology.

[19]  T. Liewluck,et al.  PD-1 Inhibitor-associated Myopathies: Emerging Immune-mediated Myopathies , 2017, Journal of immunotherapy.

[20]  M. Mauermann,et al.  The Mayo Clinic Experience With the Neurological Complications of the CTLA-4 Inhibitor Ipilimumab , 2018, The neurologist.

[21]  N. Staff,et al.  Neurological Complications Associated With Anti–Programmed Death 1 (PD-1) Antibodies , 2017, JAMA neurology.

[22]  Shigeaki Suzuki,et al.  Nivolumab-related myasthenia gravis with myositis and myocarditis in Japan , 2017, Neurology.

[23]  N. Staff,et al.  Brachial Plexus Neuritis Associated With Anti–Programmed Cell Death-1 Antibodies: Report of 2 Cases , 2017, Mayo Clinic proceedings. Innovations, quality & outcomes.

[24]  M. Brown,et al.  Autoimmune limbic encephalitis with anti-contactin-associated protein-like 2 antibody secondary to pembrolizumab therapy , 2017, Journal of Neuroimmunology.

[25]  S. Cuzzubbo,et al.  Neurological adverse events associated with immune checkpoint inhibitors: Review of the literature. , 2017, European journal of cancer.

[26]  M. Garg,et al.  Current Diagnosis and Management of Immune Related Adverse Events (irAEs) Induced by Immune Checkpoint Inhibitor Therapy , 2017, Front. Pharmacol..

[27]  J. Larkin,et al.  Neurotoxicity from immune-checkpoint inhibition in the treatment of melanoma: a single centre experience and review of the literature. , 2017, Annals of oncology : official journal of the European Society for Medical Oncology.

[28]  V. Lennon,et al.  Autoimmune Glial Fibrillary Acidic Protein Astrocytopathy: A Novel Meningoencephalomyelitis. , 2016, JAMA neurology.

[29]  E. Lipson,et al.  Association of Autoimmune Encephalitis With Combined Immune Checkpoint Inhibitor Treatment for Metastatic Cancer. , 2016, JAMA neurology.

[30]  C. Berking,et al.  CTLA4 as Immunological Checkpoint in the Development of Multiple Sclerosis , 2016, Annals of neurology.

[31]  V. Lennon,et al.  Frequency of Synaptic Autoantibody Accompaniments and Neurological Manifestations of Thymoma. , 2016, JAMA neurology.

[32]  S. Yeh,et al.  Vogt-Koyanagi-Harada-like syndrome after CTLA-4 inhibition with ipilimumab for metastatic melanoma. , 2015, Journal of immunotherapy.

[33]  K. Murphy,et al.  New-Onset Mediastinal and Central Nervous System Sarcoidosis in a Patient with Metastatic Melanoma Undergoing CTLA4 Monoclonal Antibody Treatment , 2014, Oncology Research and Treatment.

[34]  Antoni Ribas,et al.  Tumor immunotherapy directed at PD-1. , 2012, The New England journal of medicine.

[35]  Drew M. Pardoll,et al.  The blockade of immune checkpoints in cancer immunotherapy , 2012, Nature Reviews Cancer.

[36]  R. Schreiber,et al.  Cancer Immunoediting: Integrating Immunity’s Roles in Cancer Suppression and Promotion , 2011, Science.

[37]  S. Pittock,et al.  CRMP5-IgG-Associated Paraneoplastic Myelopathy With PD-L1 Inhibitor Therapy. , 2019, JAMA neurology.

[38]  A. Pruitt,et al.  A case series of PD-1 inhibitor-associated paraneoplastic neurologic syndromes , 2019, Journal of Neuroimmunology.

[39]  R. Sullivan,et al.  Varied phenotypes and management of immune checkpoint inhibitor-associated neuropathies , 2019, Neurology.

[40]  V. Lennon,et al.  Neurologic Autoimmunity in the Era of Checkpoint Inhibitor Cancer Immunotherapy. , 2019, Mayo Clinic proceedings.

[41]  F. Ducray,et al.  Increased frequency of anti-Ma2 encephalitis associated with immune checkpoint inhibitors , 2019, Neurology: Neuroimmunology & Neuroinflammation.

[42]  D. Scheie,et al.  Neuromuscular adverse events associated with anti-PD-1 monoclonal antibodies , 2018, Neurology.

[43]  V. Lennon,et al.  Paraneoplastic autoimmunity and small‐cell lung cancer: Neurological and serological accompaniments , 2019, Thoracic cancer.

[44]  A. Mammen,et al.  Pre-existing antiacetylcholine receptor autoantibodies and B cell lymphopaenia are associated with the development of myositis in patients with thymoma treated with avelumab, an immune checkpoint inhibitor targeting programmed death-ligand 1 , 2018, Annals of the rheumatic diseases.

[45]  C. Lucchinetti,et al.  Paraneoplastic neuronal intermediate filament autoimmunity , 2018, Neurology.

[46]  S. Minami,et al.  Lambert-Eaton Myasthenic Syndrome Caused by Nivolumab in a Patient with Squamous Cell Lung Cancer , 2018, Case Reports in Neurology.

[47]  N. Weiss,et al.  Immune checkpoint inhibitor-related myositis and myocarditis in patients with cancer , 2018, Neurology.

[48]  U. Topaloglu,et al.  Severe neurologic complications of immune checkpoint inhibitors: a single-center review , 2018, Journal of Neurology.

[49]  S. Irani,et al.  Seronegative antibody‐mediated neurology after immune checkpoint inhibitors , 2018, Annals of clinical and translational neurology.

[50]  M. Suarez‐Almazor,et al.  Management of Immune-Related Adverse Events in Patients Treated With Immune Checkpoint Inhibitor Therapy: American Society of Clinical Oncology Clinical Practice Guideline. , 2018, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[51]  J. Sawada,et al.  Neuromyelitis optica spectrum disorder secondary to treatment with anti-PD-1 antibody nivolumab: the first report , 2018, BMC Cancer.

[52]  M. Lotem,et al.  Neurologic complications of immune checkpoint inhibitors , 2018, Journal of Neuro-Oncology.

[53]  T. Liewluck,et al.  PD-1 Inhibitor-associated Myopathies: Emerging Immune-mediated Myopathies , 2017, Journal of immunotherapy.

[54]  M. Mauermann,et al.  The Mayo Clinic Experience With the Neurological Complications of the CTLA-4 Inhibitor Ipilimumab , 2018, The neurologist.

[55]  N. Staff,et al.  Neurological Complications Associated With Anti–Programmed Death 1 (PD-1) Antibodies , 2017, JAMA neurology.

[56]  Shigeaki Suzuki,et al.  Nivolumab-related myasthenia gravis with myositis and myocarditis in Japan , 2017, Neurology.

[57]  N. Staff,et al.  Brachial Plexus Neuritis Associated With Anti–Programmed Cell Death-1 Antibodies: Report of 2 Cases , 2017, Mayo Clinic proceedings. Innovations, quality & outcomes.

[58]  M. Brown,et al.  Autoimmune limbic encephalitis with anti-contactin-associated protein-like 2 antibody secondary to pembrolizumab therapy , 2017, Journal of Neuroimmunology.

[59]  S. Cuzzubbo,et al.  Neurological adverse events associated with immune checkpoint inhibitors: Review of the literature. , 2017, European journal of cancer.

[60]  M. Garg,et al.  Current Diagnosis and Management of Immune Related Adverse Events (irAEs) Induced by Immune Checkpoint Inhibitor Therapy , 2017, Front. Pharmacol..

[61]  V. Lennon,et al.  Autoimmune Glial Fibrillary Acidic Protein Astrocytopathy: A Novel Meningoencephalomyelitis. , 2016, JAMA neurology.

[62]  J. Larkin,et al.  Neurotoxicity from immune-checkpoint inhibition in the treatment of melanoma: a single centre experience and review of the literature , 2016, Annals of oncology : official journal of the European Society for Medical Oncology.

[63]  E. Lipson,et al.  Association of Autoimmune Encephalitis With Combined Immune Checkpoint Inhibitor Treatment for Metastatic Cancer. , 2016, JAMA neurology.

[64]  C. Berking,et al.  CTLA4 as Immunological Checkpoint in the Development of Multiple Sclerosis , 2016, Annals of neurology.

[65]  V. Lennon,et al.  Frequency of Synaptic Autoantibody Accompaniments and Neurological Manifestations of Thymoma. , 2016, JAMA neurology.

[66]  S. Yeh,et al.  Vogt-Koyanagi-Harada-like syndrome after CTLA-4 inhibition with ipilimumab for metastatic melanoma. , 2015, Journal of immunotherapy.

[67]  K. Murphy,et al.  New-Onset Mediastinal and Central Nervous System Sarcoidosis in a Patient with Metastatic Melanoma Undergoing CTLA4 Monoclonal Antibody Treatment , 2014, Oncology Research and Treatment.

[68]  Antoni Ribas,et al.  Tumor immunotherapy directed at PD-1. , 2012, The New England journal of medicine.

[69]  Drew M. Pardoll,et al.  The blockade of immune checkpoints in cancer immunotherapy , 2012, Nature Reviews Cancer.

[70]  R. Schreiber,et al.  Cancer Immunoediting: Integrating Immunity’s Roles in Cancer Suppression and Promotion , 2011, Science.